# Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1

> **NCT04860960** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Cyclo Therapeutics, Inc.** · enrollment: 94 (actual)

## Conditions studied

- Niemann-Pick Disease, Type C1

## Interventions

- **DRUG:** Hydroxypropyl-beta-cyclodextrin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04860960
- **Lead sponsor:** Cyclo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-20
- **Primary completion:** 2025-06
- **Final completion:** 2026-06
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04860960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04860960, "Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04860960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*